beauty tech

New women's health and beauty biz led by Houston entrepreneur emerges from stealth with $35M in funding

Natalie Harms
Oct 28, 2021, 2:14 pm
The new startup has acquired Birchbox and plans to relaunch the beauty subscription service with its patented health customization. Photo via birchbox.com

A Houston health tech entrepreneur who's started six businesses in his career has announced his latest endeavor.

Dr. Kimon Angelides, founder of Houston health tech startups Livongo Health and Vivante Health, launched FemTec Health, a tech-enabled women's health sciences and beauty company focused on transforming the total healthcare experience for women. The company is emerging from stealth mode this week with already 10 million members, two clinical trials in progress, and a team of over 150.

FemTec Health is building the data analytics platform to support products and services for women in every life stage. The patent-pending BiomeAI™engine uses AI and deep machine learning to translate consumer, genetic, microbiome, and biometric data into the delivery of holistic healthcare personalized for every woman, according to a news release from the company.

"Our platform can be implemented across all areas including specialty care, wellness and prevention, reproductive care, sexual wellness, mental health, chronic care, and beyond," Angelides says in the release. "It is driven by state-of-the-art genomics and digital technologies that empower women to take control of their health at every stage of their life journey, based on their individual health profiles."

Angelides serves as the new company's chairman and interim CEO. Photo via LinkedIn

FemTec has already raised more than $35 million in funding from a myriad of investors, capital, and shareholders, including Longmont Capital, Ithaca LifeSciences, Unilever Ventures, Estee Lauder, Shiseido, e.Ventures, Viking Global, and Trinity Capital.

The company, which has been in the works since May of 2020, has assembled an all-star team of experts, including Dr. Kimberly Capone, chief scientific officer (formerly with Johnson & Johnson), and Dr. Laura Clapper, COO (formerly Cigna, CVS-Aetna).

"Women's health has been under-researched and underrepresented for too long," says Capone in the release. "As a woman and a scientist, I have often been the sounding board for friends and family on their wellness journey – offering advice and feedback on skincare, vaginal care, probiotics and supplements that can help with issues in skin and vaginal health, PMS and menopause. What I hear consistently is that women do not know where to go, or what products to choose that may help."

This is exactly the need the technology will help to solve.

"This is where FemTec Health's unified and coordinated platform comes in — we provide personalized services and science-based products that are meaningful and effective for women at all stages of their lives. I believe the future is female and FemTec Health will help get us there," Capone continues.

FemTec Health's business and growth model is to expand via acquisitions — and the company has several under its belt already, including beauty subscription box Birchbox, universal beauty store Mira Beauty, and beauty industry social marketing platform Liquid Grids, which has over 1.5 million members, according to the release.

"Our first acquisitions within women's health and beauty are key to our mission to revolutionize the women's healthcare and beauty industry," says Angelides, who is the company's executive chairman and interim CEO. "Women deserve a comprehensive, all encompassing model designed specifically for them. The starting point is to really understand a woman's healthcare needs and then apply smart technology like AI and predictive analytics to translate the data into actionable outcomes."

In the near future, the company plans on re-launching Birchbox, using the BiomeAI™ platform to give subscribers curated personalized skin and healthcare products. Birchbox was sold to private equity firm, Viking Global — one of FemTec's investors, in 2018.

"I have always believed in the power of women as a community, and I believe this is a natural step in the evolution of Birchbox," says Katia Beauchamp, founder of Birchbox, in the release. "Eleven years ago, we were compelled by an ability to build deep customer relationships month after month. FemTec's vision for the future of women's healthcare was inspirational to me and I could see the opportunity for the thousands of women in the Birchbox community to extend beyond consumer beauty products to a more holistic health and wellness offering."

According to the release, more strategic partnerships with health and wellness companies will be announced soon.

femtec healthbirchboxkimon angelides

Trending News

guest column

Houston innovator explores importance of belonging within the modern workforce

HOUSTON INNOVATORS PODCAST EPISODE 205

Houston startup founders prepare to scale globally following Shark Tank success

 
 

Promoted

freshly funded

Rice researchers score $45M from NIH for cancer-fighting tech

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

From Your Site Articles
Omid VeisehReginald DesRochesRice UniversityARPA-Hamir jazaerithorhammrbiotechnational institutes of health

Trending News

guest column

Houston innovator explores importance of belonging within the modern workforce

HOUSTON INNOVATORS PODCAST EPISODE 205

Houston startup founders prepare to scale globally following Shark Tank success

 
 

Promoted